This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ocinaplon

Euthymics Bioscience, Inc.

Drug Names(s): Ocinaplon

Description: Ocinaplon was developed to be an anxioselective compound acting at the GABA-A Receptor benzodiazepine binding site.

Deal Structure: In October 2003, DOV announced that it has agreed with Elan to purchase 100% ownership of the parties' joint venture operating company established in 1999 to develop controlled release formulations of bicifadine and ocinaplon.

In July 2010, Euthymics Bioscience and DOV Pharmaceutical jointly announced that they have signed a merger agreement in connection with the pending merger and acquisition of DOV by Euthymics. The acquisition price for DOV is for up to $2.0 million in cash, payable in two installments, representing a total of approximately $0.015 per share of DOV common stock. If the transaction is consummated, it is anticipated that DOV will be renamed Euthymics Bioscience. The acquisition was completed later in July 2010.


Ocinaplon News

Pink Sheet DOV drops ocinaplon


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug